Wednesday, November 11, 2026

OpenAI's Chief Scientist Says Fully Automated AI Research Labs Are Months Away

OpenAI's chief scientist Jakub Pachocki predicts AI models capable of working indefinitely like human researchers are approaching reality, with the company pushing toward entire research labs operating autonomously in data centers. The vision comes as enterprises accelerate AI infrastructure investments despite market uncertainty, with major indices down 1.4-1.6% amid questions about AI monetization timelines.

LM Salvado

March 24, 2026

OpenAI's Chief Scientist Says Fully Automated AI Research Labs Are Months Away
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

OpenAI's chief scientist Jakub Pachocki says the company is nearing models that can "work indefinitely in a coherent way just like people do," marking a shift from AI assistants to autonomous researchers.

"I think we will get to a point where you kind of have a whole research lab in a data center," Pachocki stated in a recent interview. The advancement stems from capability improvements that let models work longer without human intervention, according to Pachocki.

OpenAI's approach centers on deploying powerful models in isolated sandboxes to prevent unintended harm while they operate autonomously. Pachocki acknowledged the challenge this poses: "I think this is a big challenge for governments to figure out."

The push toward automated research coincides with enterprise AI infrastructure buildout. Nvidia-Nebius partnerships are expanding corporate AI capabilities, while S&P Global's acquisition of Enertel signals traditional finance firms integrating AI infrastructure directly into their operations.

This convergence occurs against volatile market conditions. Major indices dropped 1.4-1.6% as the Federal Reserve maintained rate holds, suggesting investor uncertainty about AI investment returns despite aggressive infrastructure spending.

The transition from AI as tool to AI as autonomous agent carries implications for research velocity. Automated researchers could compress development cycles from years to months, but also concentrate technological advancement within companies operating large-scale data centers.

Pachocki's timeline suggests these capabilities are emerging now rather than years away. The shift from models requiring constant human supervision to those working through complex problems independently represents a threshold change in AI deployment patterns.

Enterprise adoption patterns indicate organizations are preparing for this transition. Infrastructure investments by financial services firms and AI-native companies point to expectations that autonomous AI agents will become operational tools rather than experimental projects.

The regulatory challenge Pachocki identified remains unresolved. Governments lack frameworks for overseeing AI systems that conduct research, generate intellectual property, and operate beyond human supervision timescales.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleMIT Technology Review
    OpenAI is throwing everything into building a fully automated researcher
  2. [2]News articleYahoo Finance· January 22, 2026
    4 Medical Supply Stocks Poised to Gain in a Prospering Industry
  3. [3]News articleYahoo Finance· February 24, 2026
    Agentic AI Foundation Welcomes 97 New Members As Demand for Open, Collaborative Agent Standardization Increases
  4. [4]Press releaseGlobeNewswire· March 13, 2026
    Agero Enters into Agreement to Acquire Urgently, for $5.50 in Cash Per Share, Expanding Tech-Driven Roadside Assistance Across Automotive, Fleet, Rental, and Insurance Markets
  5. [5]News articleYahoo Finance· November 26, 2025
    AI to Reshape the Global Technology Landscape in 2026, Says TrendForce
  6. [6]News articleMIT Technology Review
    Can quantum computers now solve health care problems? We’ll soon find out.
  7. [7]News articleYahoo Finance· January 30, 2026
    Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
  8. [8]News articleYahoo Finance· March 19, 2026
    Morning Brief: 3 big questions, 2 answers, and rate cut hopes remain alive
  9. [9]News articleYahoo Finance· March 17, 2026
    Nebius Teams With NVIDIA to Build Cloud for Robotics and Physical AI
  10. [10]News articleYahoo Finance· March 18, 2026
    S&P Global Acquires Enertel AI Corporation to Enhance Power Market Offering
  11. [11]News articleCrunchbase News
    The Rising Investors Behind The New Unicorn Class
  12. [12]Press releaseGlobeNewswire· March 19, 2026
    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com